Western blot shows lysates of Jurkat human acute T cell leukemia cell line, MCF‑7 human breast cancer cell line, and MDA‑MB‑453 human breast cancer cell line. PVDF membrane was probed with 1 µg/mL of Goat ...read more
Simple Western lane view shows lysates of Jurkat human acute T cell leukemia cell line, loaded at 0.2 mg/mL. A specific band was detected for c‑Abl at approximately 149 kDa (as indicated) using 10 µg/mL of Goat ...read more
c-Abl (Abelson murine leukemia viral homolog 1) is a cytosolic member of the ABL subfamily, protein tyrosine kinase family of enzymes. It is ubiquitously expressed, and participates in multiple processes such as cell migration, actin reorganization, DNA damage response and apoptosis. Human c-Abl (I-B) is 1149 amino acids (aa) in length. It is myristoylated on Gly2 and contains one SH3 domain (aa 80‑140), an SH2 domain (aa 146‑236), a protein kinase region (aa 261‑512), three NLS's (aa 620‑634; 726‑739; 778‑791), one DNA-binding region (aa 888‑988), an NES motif (aa 1109‑1119) and an actin F-binding domain (aa 1120‑1149). There is one alternate splice form (I-A) that contains a 26 aa substitution for the N-terminal 45 amino acids. In chronic myelogenous leukemia, c-Abl is fused to the Bcr gene product, resulting in the production of a constitutively active tyrosine kinase.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our c-Abl Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.